Mechanistically, it influences gene networks involved in tissue remodeling and exerts protective antioxidant and anti-inflammatory actions, partly through TGF- signaling and regulation of metalloproteinases
Die drei Studien zeigen ein einheitliches Bild: Fragmente von Thymosin beta-4 zu denen TB 500 gezielt gehrt beschleunigen in Tiermodellen die Wundheilung, verbessern die Gefssneubildung und reduzieren Narbengewebe
Under U.S
Therapeutic Goods Administration (TGA)
Researched applications In the published preclinical and clinical literature the effects of AOD-9604 are documented in the following areas: Obesity , Phase 2b failure (2007), but a complementary mechanism in combination protocols Lipolysis in animal models , robustly demonstrated (Heffernan 2001, Ng 2009) Inhibition of lipogenesis , demonstrated in hepatocytes and adipocytes Osteoarthritis and cartilage regeneration , emerging Phase 1/2 data (mLuna Pharmaceuticals 2018+) Tendinopathy , preclinical models Age-related sarcopenia (cachexia) , exploratory plans Lipodystrophy , preclinical data in animal models Hyperlipidemia , secondary endpoints in Phase 2 trials Science & studies 4.1 Key publications Heffernan M., Summers R.J., Thorburn A., et al